Literature DB >> 22392319

What should we know about metabolic syndrome and lipodystrophy in AIDS?

Dario Jose Hart Pontes Signorini1, Michelle Carreira Miranda Monteiro, Marion de Fátima Castro de Andrade, Dario Hart Signorini, Walter de Araújo Eyer-Silva.   

Abstract

OBJECTIVE: Prevalence of chronic complications of HIV infection is increasing and early recognition and treatment of the components of metabolic syndrome (MS) are essential to prevent cardiovascular and metabolic complications. Considering this, we performed a cross-sectional study on the prevalence and risk-factors for MS among HIV-infected subjects.
METHODS: A total of 819 patients followed at a large outpatient HIV unit were assessed by an interviewer-administered questionnaire that recorded several demographic, epidemiologic, clinical, laboratory, and social variables. Lipodystrophy diagnosis relied on agreement between patient's self-report and physician's observation of altered body-fat deposits. The presence of three or more of the following characteristics identified MS: increased waist circumference, hypertriglyceridemia, low HDL cholesterol level, hypertension, and hyperglycemia. We used logistic regression analyses to study variables independently associated with MS.
RESULTS: The prevalence of MS was 20.6% and that of lipodystrophy was 38.5%. 61 (36.1%) out of 169 patients with MS had also lipodystrophy. Patients with metabolic syndrome were significantly more likely to be older (OR = 1.08), had higher CD4 counts (OR = 1.001), had an increased body mass index (OR = 1.27) and had longer exposure to antiretroviral therapy (OR = 1.01) than those without metabolic syndrome.
CONCLUSION: Both traditional risk factors for cardiovascular disease and factors associated with HIV infection itself, such as an increased CD4 cell count and a longer exposure to antiretroviral therapy, seem to be associated with metabolic syndrome in the present study population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22392319

Source DB:  PubMed          Journal:  Rev Assoc Med Bras (1992)        ISSN: 0104-4230            Impact factor:   1.209


  6 in total

Review 1.  Prevalence of cardiometabolic syndrome in HIV-infected persons: a systematic review.

Authors:  Minyahil Woldu; Omary Minzi; Ephrem Engidawork
Journal:  J Diabetes Metab Disord       Date:  2020-06-09

2.  Discordance between body mass index and anthropometric measurements among HIV-1-infected patients on antiretroviral therapy and with lipoatrophy/lipohypertrophy syndrome.

Authors:  Lismeia Raimundo Soares; Daniela Cardeal da Silva; Claudio R Gonsalez; Felipe G Batista; Luiz Augusto M Fonseca; Alberto J S Duarte; Jorge Casseb
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015 Mar-Apr       Impact factor: 1.846

3.  Adolescents with HIV and facial lipoatrophy: response to facial stimulation.

Authors:  Jesus Claudio Gabana-Silveira; Laura Davison Mangilli; Fernanda C Sassi; Arnaldo Feitosa Braga; Claudia Regina Furquim Andrade
Journal:  Clinics (Sao Paulo)       Date:  2014-08       Impact factor: 2.365

Review 4.  HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settings.

Authors:  Julia L Finkelstein; Pooja Gala; Rosemary Rochford; Marshall J Glesby; Saurabh Mehta
Journal:  J Int AIDS Soc       Date:  2015-01-15       Impact factor: 5.396

5.  A Meta-Analysis of the Metabolic Syndrome Prevalence in the Global HIV-Infected Population.

Authors:  Kim A Nguyen; Nasheeta Peer; Edward J Mills; Andre P Kengne
Journal:  PLoS One       Date:  2016-03-23       Impact factor: 3.240

6.  Metabolic syndrome in HIV-infected middle-aged women on antiretroviral therapy: prevalence and associated factors.

Authors:  Lívia D Akl; Ana L R Valadares; Monica Jacques de Moraes; Aarão M Pinto-Neto; Bianca Lagrutta; Lúcia Costa-Paiva
Journal:  Braz J Infect Dis       Date:  2017-03-08       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.